Form 4: Schrodinger Director Gary Sender Reports Stock and Option Awards

Director Gary Sender reports the acquisition of stock and option awards in Schrodinger, Inc.

Summary

• Gary Sender, a director of Schrodinger, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On June 18, 2024, Sender was granted 5,000 restricted stock units (RSUs) and an option to purchase 8,550 shares of common stock.
• The RSUs and options were granted under the Issuer's 2022 Equity Incentive Plan.
• The RSUs vest on the twelve-month anniversary of the grant date (or earlier, if the next annual meeting occurs sooner), contingent upon continued service.
• The options also vest on the twelve-month anniversary of the grant date (or earlier, if the next annual meeting occurs sooner), contingent upon continued service.
• Following the reported transactions, Sender beneficially owns 11,250 shares of common stock, including 5,000 unvested RSUs, and options to purchase 8,550 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard equity grant, which is generally viewed positively as it aligns management interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options aligns the director's interests with the long-term performance of the company.
• The vesting schedule incentivizes continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted equity.

Industry Context

This type of equity grant is a common practice in the biotech and pharmaceutical industries to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity grants to directors are a standard practice across publicly traded companies, particularly in the technology and pharmaceutical sectors.
• Companies like Relay Therapeutics, Recursion Pharmaceuticals, and Exscientia also utilize stock options and RSUs as part of their compensation packages for directors and executives.
• The vesting schedules, typically one to four years, are also consistent with industry norms to ensure long-term alignment with company goals.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, incentivizing actions that increase shareholder value.

Key Dates